What happens to liver enzymes in NMRI mice given rosuvastatin?
Rosuvastatin is a statin that can affect liver biochemistry. In NMRI mice, the key liver-enzyme readouts researchers typically track are serum enzymes such as ALT (alanine aminotransferase), AST (aspartate aminotransferase), and ALP (alkaline phosphatase), because changes in these markers can indicate hepatocellular or cholestatic stress.
However, the effect size and direction (increase vs. decrease) depend on factors that vary a lot between studies, including:
- Dose and treatment duration of rosuvastatin
- Route of administration
- Baseline health of the animals
- Whether the experiment includes a liver injury model (e.g., induced toxicity) or tests only drug effects
- How liver enzymes are measured (serum chemistry vs. liver homogenate activity)
Does rosuvastatin increase ALT/AST or protect the liver in NMRI mice?
Across preclinical literature broadly, statins can show two patterns depending on context:
- In drug-only settings, some studies report mild elevations in ALT/AST, consistent with low-grade hepatocellular stress.
- In toxicity-injury models, rosuvastatin sometimes reduces damage and normalizes enzymes, consistent with protective effects.
So, for NMRI mice specifically, rosuvastatin’s observed effect on liver enzymes usually follows the logic of the model: if the study uses an experimental liver injury, rosuvastatin often improves enzyme elevations caused by the injury. If it’s a baseline, non-injury design, rosuvastatin may cause little change or small increases, depending on dose and duration.
Which liver enzymes are most often measured (ALT, AST, ALP) and what would “effect” look like?
When investigators say “effect on liver enzymes,” they usually mean one or more of:
- ALT and AST: hepatocellular injury markers. An increase typically indicates liver cell membrane damage or leakage into blood.
- ALP: often reflects biliary/liver stress.
- Sometimes additional markers like bilirubin or oxidative stress enzymes are also included, but ALT/AST/ALP are the most common.
What to look for in results is whether rosuvastatin compared with control shows:
- A statistically significant rise in ALT/AST/ALP (suggesting enzyme induction or liver stress), or
- A significant reduction of enzyme elevations (suggesting protection against injury)
What experimental details most strongly change the result?
If you’re trying to interpret or reproduce the findings, the following design details matter most:
- Dose (higher doses more often show enzyme elevations)
- Duration (short exposure may show different effects than repeated dosing)
- Vehicle and administration route (oral vs. intraperitoneal can differ)
- Presence/absence of a hepatotoxic challenge (CCl4, acetaminophen, etc.)
- Sample timing (enzymes can peak and then normalize)
Can I get a specific answer for your exact study (dose and duration)?
To give a precise “rosuvastatin caused X change in ALT/AST/ALP in NMRI mice” answer, I’d need the study conditions. If you share:
- rosuvastatin dose (mg/kg) and route
- treatment duration (days/weeks)
- whether the mice were injured with a toxin/drug (and which one)
- which enzymes were measured and at what time point
…I can translate the expected direction and what the findings usually mean.
Sources
No source links or study results were provided with your question, so I can’t cite a specific NMRI-mouse rosuvastatin study or numeric enzyme changes.